JPMorgan Chase & Co. reaffirmed their top pick rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a report issued on Tuesday, The Fly reports. Several other research analysts have also recently weighed in on XENE. Needham & Company LLC reissued a buy rating and issued a $50.00 price objective on shares of […]
Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a note issued to investors on Friday, Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 26.94% […]
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the thirteen ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average twelve-month price […]
Royal Bank of Canada restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a research note published on Wednesday, Benzinga reports. The firm currently has a $51.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on XENE. Needham & Company LLC increased […]
Royal Bank of Canada restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a report issued on Wednesday, Benzinga reports. The brokerage currently has a $51.00 price target on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued reports about the company. The Goldman Sachs Group assumed […]